ISPENTelesta has already as an agreement with Ispen to commercialize MNCA in Europe for $149 Million and $25 Million in milestone payment. However the process remains the same. Ispen has to get an approval from respective countries. It will take around 5 years to fully market MNCA. I am refering to the news release before FDA F-UP in North America in late October.
It's not even a month or to be exact since Feburary 2 that share are fooked. Come on, give it atleast 3 months or listen to Telesta with the results of A1 type meeting with FDA on Feb 27. Even with phase III trial results, Telesta will find a way to respond to upside market. It's just the management needs more time to understand MCNA's efficacy of the treatment for NMIBC.
Lets hope there are no shortages and ISPEN can break a deal in U.K, Germany or with some major country in Europe. I am in it since 0.59 and its worth to wait a while.